Survival Endpoints, Rigorous Phase IIs May Boost Cancer Vaccines’ Success
Executive Summary
SAN FRANCISCO - Stronger endpoints for survival and more rigorously designed Phase II trials are what will push the development of therapeutic cancer vaccines closer to the finish line, an industry panel said at a recent meeting at the Biotechnology Industry Organization Investor Forum